ASO Author Reflections: Neoadjuvant Systemic Therapy and Nodal Management in cT1-2 N0 Triple-Negative Breast Cancer

Ann Surg Oncol. 2024 May;31(5):3196-3197. doi: 10.1245/s10434-024-15020-6. Epub 2024 Feb 10.

Authors

Chandler S Cortina^{1

2}, Christine C Rogers³, Mediget Teshome⁴

Affiliations

¹ Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA. ccortina@mcw.edu.
² Medical College of Wisconsin Cancer Center, Milwaukee, WI, USA. ccortina@mcw.edu.
³ Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴ Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 38341380
PMCID: PMC11003827 (available on 2025-05-01)
DOI: 10.1245/s10434-024-15020-6

No abstract available

MeSH terms

Axilla
Breast Neoplasms* / drug therapy
Female
Humans
Neoadjuvant Therapy
Receptor, ErbB-2
Sentinel Lymph Node Biopsy
Triple Negative Breast Neoplasms* / drug therapy

Substances

Receptor, ErbB-2

Grants and funding